RESUMEN
BACKGROUND: Ingestion of flakes of Pb-based paint by infants remains a global health hazard with life-long consequences. Pb-based paint was banned for residential use in the US and Western Europe decades ago but is still sold in many countries. This study evaluates the performance of a new kit for detecting exposed Pb-based paint relying on the formation of Pb-halide perovskite that fluoresces bright green under a UV flashlight after spraying a non-toxic reagent. RESULTS: Tests with the Lumetallix kit were conducted in parallel with X-fluorescence and inductively-coupled plasma atomic emission analysis upon acid digestion using paint currently sold in Côte d'Ivoire and samples of older US paint. Comparison of the three different methods indicates a detection limit for the Lumetallix kit of approximately 500 mg kg-1 (ppm) Pb in paint, with a sensitivity of 95 % and selectivity of 94 % relative to that threshold (n = 76). This detection limit is an order of magnitude below the US definition of Pb-based paint of 0.5 % (5,000 ppm) Pb by weight. SIGNIFICANCE: Because the kit is easy to use, exposed paint posing a risk could reliably be screened at scale by the general public. Any follow-up for confirmation and mitigation based on XRF measurements will need to consider that Pb-based paint covered with low-Pb paint will not respond to the kit but will be detected by XRF through the overpainted layer.
RESUMEN
BACKGROUND: Inorganic arsenic is metabolized to monomethyl- (MMAs) and dimethyl- (DMAs) species via one-carbon metabolism (OCM); this facilitates urinary arsenic elimination. OCM is influenced by folate and vitamin B12 and previous randomized control trials (RCTs) showed that folic acid (FA) supplementation increases arsenic methylation in adults. This RCT investigated the effects of FA + B12 supplementation on arsenic methylation in children, a key developmental stage where OCM supports growth. METHODS: A total of 240 participants (8-11 years, 53 % female) drinking from wells with arsenic concentrations > 50 µg/L, were encouraged to switch to low arsenic wells and were randomized to receive 400 µg FA + 5 µg B12 or placebo daily for 12-weeks. Urine and blood samples were collected at baseline, week 1 (only urine) and week 12. Generalized estimated equation (GEE) models were used to assess treatment effects on arsenic species in blood and urine. RESULTS: At baseline, the mean ± SD total blood and urinary arsenic were 5.3 ± 2.9 µg/L and 91.2 ± 89.5 µg/L. Overall, total blood and urine arsenic decreased by 11.7% and 17.6%, respectively, at the end of follow up. Compared to placebo, the supplementation group experienced a significant increase in the concentration of blood DMAs by 14.0% (95% CI 5.0, 25.0) and blood secondary methylation index (DMAs/MMAs) by 0.19 (95% CI: 0.09, 0.35) at 12 weeks. Similarly, there was a 1.62% (95% CI: 0.43, 20.83) significantly higher urinary %DMAs and -1.10% (95% CI: -1.73, -0.48) significantly lower urinary %MMAs in the supplementatio group compared to the placebo group after 1 week. The direction of the changes in the urinary %iAs, %MMAs, and %DMAs at week 12 were consistent with those at week 1, though estimates were not significant. Treatment effects were stronger among participants with higher baseline blood arsenic concentrations. Results were consistent across males and females, and participants with higher and lower folate and B12 status at baseline. CONCLUSION: This RCT confirms that FA + B12 supplementation increases arsenic methylation in children as reflected by decreased MMAs and increased DMAs in blood and urine. Nutritional interventions may improve arsenic methylation and elimination in children, potentially reducing arsenic toxicity while also improving nutritional status.